Alcidion Group Limited (ALC) AI Stock Analysis

• Market Cap: AU$124.89M
• Dividend Yield: N/A
• Average Volume (3M): 1.44M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.76
• Revenue Growth: -11.96%
• EPS Growth: 7.50%
• Country: AU
• Employees: 145
• Sector: Healthcare
• Sector Strength: 58
• Industry: Medical - Healthcare Information Services
• EPS (TTM): >-0.01
• Shares Outstanding: 1,342,952,600
• 10 Day Avg. Volume: 2,230,519
• 30 Day Avg. Volume: 1,443,583
• PEG Ratio: -0.56
• Price to Book (P/B): 1.37
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 763.63
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$0.11
• Price Target Upside: 22.22% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 54 Neutral
• Price Target: AU$0.00 ▼(-100.00%Downside)

The overall stock score is primarily influenced by financial performance challenges, including negative profitability and cash flow issues. Technical analysis provides some support with a positive momentum trend. However, poor valuation metrics, especially a negative P/E ratio, weigh heavily on the stock's attractiveness. The lack of earnings call data and corporate events means these factors do not impact the score.

Alcidion Group Limited Business Overview & Revenue Model

Company Description

Alcidion Group Limited (ALC) is a health informatics company that operates within the healthcare technology sector. The company specializes in developing and delivering innovative software solutions designed to improve healthcare delivery and patient outcomes. Its core products include Miya Precision, a smart clinical decision support platform, and various other tools focused on enhancing clinical workflows, patient safety, and hospital operations efficiency.

How the Company Makes Money

Alcidion Group Limited generates revenue primarily through the sale and licensing of its software solutions to healthcare providers such as hospitals and health systems. The company's key revenue streams include subscription fees for its software-as-a-service (SaaS) offerings, implementation and integration services, and ongoing support and maintenance contracts. Additionally, Alcidion forms strategic partnerships with other healthcare technology providers and institutions to expand its market reach and enhance its product offerings, which can also contribute to its revenue growth.

Alcidion Group Limited Financial Statement Overview

Summary

Alcidion Group Limited faces challenges with profitability and cash generation, despite a strong equity base and low leverage. The company needs to improve operational efficiency and stabilize revenue growth to enhance financial stability. Continued losses and negative cash flows are areas of concern.

Income Statement

The company has shown volatility in its revenue with a decrease from the previous year. Gross profit margin is strong at approximately 86.1%, but net profit margin is deeply negative due to substantial losses. EBIT and EBITDA margins are also negative, indicating operational inefficiencies and high operating costs.

Balance Sheet

The company maintains a strong equity position with an equity ratio of approximately 75.9%. However, consistent losses have led to a negative return on equity. The debt-to-equity ratio is low at 0.02, indicating minimal leverage which poses less financial risk.

Cash Flow

Cash flow from operations is negative, and free cash flow has decreased from the previous year, indicating challenges in generating cash from core activities. The free cash flow to net income ratio is negative, reflecting operational difficulties.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
35.64M	37.06M	40.40M	34.35M	25.88M	18.55M
	Gross Profit
30.55M	31.92M	1.25M	3.29M	3.52M	401.23K
	EBIT
1.68M	-7.65M	-4.73M	-1.73M	-174.00K	-2.32M
	EBITDA
-3.50M	-4.50M	-1.43M	-1.58M	-474.00K	-3.77M
	Net Income Common Stockholders
-4.97M	-8.42M	-3.62M	-4.41M	-2.24M	-3.08M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
7.91M	11.80M	14.64M	17.34M	25.03M	15.95M
	Total Assets
116.04M	114.46M	120.68M	128.35M	58.38M	39.43M
	Total Debt
2.08M	1.70M	2.15M	2.48M	181.00K	315.85K
	Net Debt
-5.84M	-10.10M	-12.49M	-14.86M	-24.85M	-15.63M
	Total Liabilities
24.89M	27.52M	30.52M	34.40M	13.16M	9.70M
	Stockholders Equity
91.16M	86.94M	90.17M	93.95M	45.22M	29.74M
Cash Flow		Free Cash Flow
153.00K	-7.18M	-285.00K	685.00K	1.23M	-2.14M
	Operating Cash Flow
171.00K	-7.13M	169.00K	996.00K	1.54M	-2.02M
	Investing Cash Flow
-18.00K	-53.00K	-3.14M	-59.74M	-9.84M	-362.04K
	Financing Cash Flow
-688.00K	4.34M	-616.00K	51.33M	17.23M	15.16M

Alcidion Group Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.09
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ALC, the sentiment is Positive. The current price of 0.09 is above the 20-day moving average (MA) of 0.09, above the 50-day MA of 0.08, and above the 200-day MA of 0.07, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 62.46 is Neutral, neither overbought nor oversold. The STOCH value of 70.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:ALC.

Alcidion Group Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADH	73 Outperform	AU$480.74M	13.78	14.57%	4.78%	0.49%	-3.64%
CTE	66 Neutral	AU$36.36M	19.87	87.09%	2.68%	1.86%	16.10%
RHT	61 Neutral	AU$18.84M	140.00	-3.11%	―	89.13%	69.57%
ALC	54 Neutral	AU$124.89M	―	-5.63%	―	-11.96%	7.50%
Sector *	54 Neutral	$5.41B	3.27	-45.10%	3.29%	16.81%	0.02%
IDX	51 Neutral	AU$860.31M	94.24	1.14%	2.16%	7.83%	―

Alcidion Group Limited Corporate Events

Alcidion Group Limited Announces Cessation of Performance Rights

Alcidion Group Limited announced the cessation of 206,458 performance rights due to the lapse of conditional rights that were not satisfied by the specified date. This development may impact the company’s capital structure and could have implications for stakeholders as it reflects on the company’s performance metrics and strategic objectives.

The most recent analyst rating on (AU:ALC) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.

Alcidion Announces Board Change with Director Departure

Alcidion Group Limited has announced a change in its board of directors, with Victoria Weekes ceasing to be a director as of May 30, 2025. This update, in compliance with ASX Listing Rule 3.19A.3, is part of the company’s ongoing corporate governance and may impact its strategic direction as it continues to expand its healthcare technology services globally.

The most recent analyst rating on (AU:ALC) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.

Alcidion Group to Release Q3 FY25 Results and Host Investor Webcast

Alcidion Group Limited announced the release of its Appendix 4C and Quarterly Cash Flow Report for Q3 FY25, scheduled for April 22, 2025. A live webcast will be hosted by the company’s CEO and CFO to discuss the quarter’s operational and commercial highlights, offering stakeholders insights into the company’s performance and strategic direction.

Alcidion Group Appoints New Director to Strengthen Leadership

Alcidion Group Limited has announced the appointment of Andrew Way as a director, effective from April 15, 2025, as per the ASX listing rule 3.19A.1. This appointment is part of Alcidion’s ongoing efforts to strengthen its leadership team, potentially impacting its strategic direction and market positioning in the healthcare technology sector.

Alcidion Appoints Professor Andrew Way AM as Non-Executive Director

Alcidion Group Limited has announced the appointment of Professor Andrew Way AM as a Non-Executive Director, succeeding Victoria Weekes who will step down mid-year. Professor Way brings extensive experience in healthcare management and IT, aligning with Alcidion’s mission to support the healthcare industry. His appointment is part of Alcidion’s strategic plan to scale the company and expand its customer base, leveraging his expertise in quality patient care and healthcare systems.